Page 23 - FLIPBOOK
P. 23
In intermittent ADT, agonist’s reinjection for a new cycle of treatment causes
repeated T and FSH surges, linked with an increase risk of CV events in
patients.
▪ 1134 randomized to continuous vs. Adverse Health Event HR for p-
intermittent ADT on S9346 (2) continuous ADT
▪ 636 (56%) of trial participants had Ischemic and Thrombotic Events 0.48 .02
≥1 year of continuous Medicare
parts A&B coverage and no HMO Acute MI 0.57 .22
participation.
Ischemic Heart Disease 0.35 .04
Thrombosis (severe) 0.79 .57
Hershman DL et al. JAMA Oncol. 2016 2(4):453-61.